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Selective-sampling Raman imaging techniques
for ex vivo assessment of surgical margins in
cancer surgery
Maria Giovanna Lizio, † Radu Boitor† and Ioan Notingher*
One of the main challenges in cancer surgery is to ensure the complete excision of the tumour while
sparing as much healthy tissue as possible. Histopathology, the gold-standard technique used to assess
the surgical margins on the excised tissue, is often impractical for intra-operative use because of the
time-consuming tissue cryo-sectioning and staining, and availability of histopathologists to assess stained
tissue sections. Raman micro-spectroscopy is a powerful technique that can detect microscopic residual
tumours on ex vivo tissue samples with accuracy, based entirely on intrinsic chemical differences.
However, raster-scanning Raman micro-spectroscopy is a slow imaging technique that typically requires
long data acquisition times wich are impractical for intra-operative use. Selective-sampling Raman
imaging overcomes these limitations by using information regarding the spatial properties of the tissue to
reduce the number of Raman spectra. This paper reviews the latest advances in selective-sampling
Raman techniques and applications, mainly based on multimodal optical imaging. We also highlight the
latest results of clinical integration of a prototype device for non-melanoma skin cancer. These promising
results indicate the potential impact of Raman spectroscopy for providing fast and objective assessment
of surgical margins, helping surgeons ensure the complete removal of tumour cells while sparing as
much healthy tissue as possible.
Introduction
It is estimated that, worldwide, 24.5 million new cancer cases
are diagnosed each year, with approximately 9.6 million
cancer-related deaths.1 Surgery is the main treatment option
for most cancer patients. The main challenge in cancer
surgery is to remove the entire tumour while minimising the
amount of healthy tissue being excised. The standard pro-
cedure to check the completeness of tumour removal is his-
tology of paraffin embedded tissues.2 Using hematoxylin and
eosin (H&E) stained sections, histology measures the distance
from the tumour edge to the surface of the excised tissue (sur-
gical margins), which provides an indication on whether all
tumour had been successfully removed or not. However, his-
tology using paraffin embedded tissue is time-consuming and
is performed post-operatively only. The availability of accurate
techniques for checking the completeness of tumour excision
intra-operatively could improve the outcomes of cancer
surgery, as surgeons could check the excision margins while
the patient is still in the operative theatre and could therefore
excise additional tissue if needed. For this purpose, techniques
that have high sensitivities and specificities for detection of
tumour as well as a high spatial resolution, are required.
Intraoperative frozen section histology3,4 is a faster alterna-
tive to paraffin embedded histology, as tissue freezing, cryosec-
tioning, staining and evaluation can be completed within
20–90 minutes.5 However, the quality of the frozen H&E sec-
tions is lower than for paraffin embedded staining, and
sampling errors (typically < 1% of the excision surface) and
freezing artifacts have limited its use.3,5 Currently, frozen
section histology is adopted only in some specialised sur-
geries, such as Mohs surgery (evaluates 100% of excision
surface),5,6 explorative surgeries7 or assessment of sentinel
nodes.8
A wide range of optical techniques have been proposed for
intraoperative assessment of surgical margins of the resected
tissues, including optical coherence tomography,9–11 laser-
induced fluorescence imaging,12,13 two-photon excited auto-
fluorescence,14 second harmonic generation,15–17 Coherent
anti-Stokes Raman scattering imaging, Fourier transform
infrared (FTIR)18–20 and Fluorescence Life Time microscopy.21
Optical techniques have the potential to provide information
at high spatial resolution (the diffraction limit of light is lower
than the size of cells) and high contrast based on physical or
chemical differences between normal tissue and cancerous†Equal contribution.
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tissue. Raman spectroscopy uses light to measure the mole-
cular composition of tissue without requiring sectioning,
staining or labelling.22 A key feature of Raman spectroscopy is
the ability to develop multivariate classification models for
quantitative and objective diagnosis of the samples.22–25
Raman microscopy can produce high-resolution diagnosis
maps of fresh ex vivo tissue specimens, on which cancer cells
are identified based on endogenous molecular contrast,
without requiring subjective interpretation of morphological
features, which are known to cause inter observer
variability.26–28
During the last two decades, Raman spectroscopy has been
used to discriminate between tumour and normal tissues on
samples from various anatomical locations, including some
related to the most common types of cancer: skin,29,30
breast,31,32 oesophagus33 and lung.34 Hand-held fibre optic
Raman probes have been used to identify positive margins in
breast, brain, oesophagus, cervical cancer and gastric dysplasia
surgery,35–38 demonstrating the potential for intra-operative
diagnosis. Nevertheless, for many cancer types, the spatial
resolution required is difficult (or impossible) to achieve with
hand-held Raman probes that measure single point spectra.
Typical examples are Mohs micrographic surgery of non-mela-
noma skin cancers (residual infiltrative tumours as small as
tens of μm) and residual tumour of ductal carcinoma in situ
(DCIS, smaller than 1 mm), which is responsible for the
higher rates of re-excision due to positive margins in breast
cancer surgery.39
Raman spectroscopy can be implemented in microscopes
with scanning modalities to generate Raman maps of tissues.
However, one main limitation of Raman micro-spectroscopy is
the relatively low Raman scattering cross-section for most of
the relevant molecules found in tissues. While this is not
a significant issue in conventional single-point Raman
measurements, acquiring Raman maps with a spatial resolu-
tion of 50 μm would require acquisition times of several hours,
which is not compatible with intraoperative timescale of
20–30 minutes.30
To overcome this limitation, different modalities of Raman
spectroscopy have been reported with the aim to reduce the
acquisition time while retaining high spatial resolution. For
example, surface–enhanced Raman spectroscopy (SERS)40,41
uses functionalized gold nanoparticles that can enhance the
Raman signals by several orders of magnitude. The potential of
such approaches for assessing surgical margins have been
shown recently for breast cancer.42 Coherent anti-stoke Raman
Scattering (CARS) microscopy has been used for brain cancer
margin assessment and a miniaturized CARS endoscope was
used for intraoperative imaging of prostate cancer.43,44 CARS
has also been used in combination with two-photon excited
fluorescence for in vivo imaging during brain surgery.45 Another
strategy for reducing the acquisition time in Raman mapping is
to reduce the number of Raman spectra by optimising the
location of the sampling points to target the regions of the
tissue that are most likely to contain tumour. This can be
achieved by either using adaptive sampling algorithms to calcu-
late locations of new sampling points in real-time, or by using a
faster screening technique that can obtain a map of the tissue
surface, which can be used to direct the Raman spectroscopy
measurements. In this set-up, Raman spectra can be recorded
from fewer locations without sacrificing the diagnosis accuracy.
This approach (selective-sampling Raman spectroscopy) can
drastically reduce the time required to assess the surgical
margins of large tissue specimens when compared to raster
scanning Raman microscopy. This review describes the latest
developments in selective-sampling Raman spectroscopy and its
applications on ex vivo tumour resections for the intraoperative
assessment of surgical margins.
Multi-modal selective sampling Raman spectroscopy
Raman mapping by raster scanning has been widely used for
acquiring high-resolution maps of tissues. Investigation of sur-
gical margins has shown that tumours tend to be co-localised
in clusters within the tissue specimens.46–48 Due to this high
level of spatial correlation, it is not necessary to maintain the
same level of spatial resolution over the entire surface of the
excised tissue. For example, the sampling density for Raman
spectroscopy can be reduced in large areas of normal tissue in
favour of higher sampling density in the regions with higher
likelihood of containing residual tumour. High resolution
images of the tissue surface obtained by other optical modal-
ities can be used to adapt the sampling density and target the
Raman spectroscopy measurements towards regions that have
a high probability of containing residual cancer cells.
Rowlands et al. showed that selective-sampling Raman spec-
troscopy can approximate raster scans when new Raman
spectra were acquired in areas selected by an algorithm that
used interpolation of information obtained from previously
measured Raman spectra (Fig. 1a).49–51 By calculating the
difference between two interpolating surfaces (a cubic spline
and a Kriging interpolation), the regions of the sample with
the highest spectral variations were selected for further Raman
spectroscopy measurements so that the sampling density was
higher in the areas of the sample with higher spectral hetero-
geneity. Another approach for selective sampling was
described by Zhang et al. which obtained Raman spectral
images of bisulfate mixtures comparable to raster scan images
(error of less than 0.5%) using only ∼16% of the spectra
required for a raster scan.52 For this method, the locations of
the new sampling positions (following an initial seed of
measurements) were directed towards pixel locations that
maximized the expected reduction in distortion, with each
spectrum being classified by a multivariate classification
model (LDA-SVM). While such selective sampling methods can
reduce the number of required Raman spectra, they also have
some limitations. For instance, in order to retain the improve-
ments in measurement speed, small tissue structures may be
missed or under-sampled. The algorithms can be optimised to
increase the likelihood of capturing smaller spatial features by
increasing the number of spectra, however, to adequately
detect features that are in the order of tens of μm, the increase
in measurement speed over raster scanning is minimal.
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Another option, to target the Raman sampling points more
effectively to tissue structures of interest (such as tumours), is
to measure the spatial properties of the sample, at the required
spatial resolution, prior to acquiring the Raman spectra. For
this purpose, alternative imaging techniques can be used, as
long as they are fast and have high sensitivity to the required
features of interest. Such optical techniques include confocal
fluorescence microscopy,46,47,53 high-wavenumber Raman
spectroscopy,54 coherent anti-Stokes Raman-scattering, second
harmonic generation55,56 and quantitative phase microscopy.57
These techniques can be used to identify regions of interest in
the samples and screen out regions that can be confidently
identified as normal tissue. For surgical margin assessment in
cancer surgery, the imaging techniques must have high sensi-
tivity for detecting tumour but not necessarily high specificity
(Fig. 1b). The decision on whether a particular region, depicted
as a segment, contains cancer or not is made after the acqui-
sition of Raman spectra and application of a multivariate spec-
tral classification model. As these imaging techniques are
much faster than confocal Raman microscopy, a large pro-
portion of the resection margin can be investigated in several
minutes. Furthermore, if the generated segments are homo-
geneous, only a small number of Raman spectra need to be
acquired within each segment for an accurate detection,
regardless of actual segment size. This multimodal approach
can result in the investigation of centimetre sized tissue speci-
mens in less than an hour.24,46,58,59 This measurement pro-
cedure is called multimodal spectral histopathology (MSH).
Assessment of surgical margins in Mohs micrographic surgery
of basal cell carcinoma (BCC)
Basal cell carcinoma (BCC) is the most common type of cancer
in the world, with ∼5.7 million cases diagnosed worldwide 1.
Mohs micrographic surgery is the treatment with the lowest
rate of tumour recurrence and is mostly used to treat lesions
occurring on the head-and-neck, large (>2 cm) and recurrent
BCCs.60–62 In Mohs surgery, sequential thin layers of skin are
removed and analysed by frozen section histology to check for
residual tumour.5 While effective at removing the tumour with
minimal damage to healthy tissue, Mohs surgery is expensive
due to its reliance on frozen section histopathology and avail-
ability of specialist surgeons trained to interpret histopathol-
ogy sections.63 Selective-sampling Raman spectroscopy that
uses auto-fluorescence (AF) imaging to direct the Raman
measurements is investigated for intra-operative assessment of
surgical margins in Mohs surgery, as a potential replacement
to frozen section histology.
Firstly, Na et al. reported the use of a 370 nm laser exci-
tation to acquire the auto-fluorescence emission spectra of
BCC and of the surrounding normal tissue from 21 lesions, to
determine the differences between the two tissue types.64 The
emission intensity of the peaks in the spectral region between
420 nm and 500 nm was observed to be 53% lower for BCC
compared to healthy tissue. The emission spectral band in
this range corresponds mainly to collagen (a structural com-
ponent of normal dermis), with small contributions from nico-
tinamide adenine dinucleotide (NADH) and keratin.65,66
Therefore, auto-fluorescence spectroscopy has a high sensi-
tivity of detecting BCC, but not sufficient specificity, as regions
of BCC could be confused with other normal tissue structures
that have low collagen composition, such as epidermis, hair
follicles, fat, sebaceous glands, etc (Fig. 1b).66
Kong et al. tested the use of wide-field auto-fluorescence
images, recorded using 292 nm and 357 nm excitation, as well
as confocal auto-fluorescence images acquired with a
457.9 nm excitation as possible screening techniques for selec-
tive-sampling Raman spectroscopy.46 While both techniques
were able to highlight the location of BCC, auto-fluorescence
confocal imaging was preferred as it produced more detailed
images with a higher contrast for thick tissue specimens.
Auto–fluorescence confocal imaging was able to record images
of 2 cm2 tissue surfaces in less than 2 minutes and correctly
classified typically more than 50% of the healthy tissue
surface. Segmentation algorithms were developed to group the
remaining tissue surface into regions of similar auto-fluo-
Fig. 1 Methods for selective sampling: (a) adaptive selective sampling
based on real time estimation of sampling points (reproduced from ref. 49
with permission from Journal of Biophotonics, copyright 2012). Basal cell
carcinoma is depicted in red in the Raman maps, which is confirmed by
histopathology. The 30× reduction in the number of acquired spectra
resulted in minimal changes to the morphology of BCC between the two
maps; (b) stratified sampling based on multi-modal approach (reproduced
from ref. 46 with permission from PNAS, copyright 2013). Arrowheads
point towards regions of low AF intensity which are further sampled via
Raman spectroscopy (blue – BCC; green – non-BCC). The multimodal
spectral histopathology (MSH) map shows the same relevant information
as the raster scan and the histopathology section.
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rescence intensity.67 Sampling points were generated within
the generated segments and the recorded Raman spectra
(785 nm excitation) were used to produce the final diagnosis
with the use of a multivariate classification model.
Kong et al. investigated frozen tissue specimen sections
from 75 patients to develop a fully automated measurement
and analysis protocol that was implemented to allow user-
independent analysis of new skin samples.46 The measure-
ments were performed with a microscope-based instrument,
for which the only manual operation was switching between
the two microscope objectives required for AF imaging and
Raman spectroscopy. The Raman spectral classification model
had a sensitivity of 95% and a specificity of 94% for the detec-
tion of BCC. BCC was identified based on the relative changes
in intensity of Raman bands corresponding to DNA and pro-
teins (O–P–O symmetric stretching 788 cm−1, PO2- stretching
at 1098 cm−1, 851 and 950 cm−1 bands assigned to proline
and hydroxyproline, etc), as suggested by previous
reports.30,49,68 To build the multivariate model, Raman spectra
were acquired via raster scanning, grouped using k-means clus-
tering and labelled according to H&E staining obtained from
the same section. The model was trained with 492 spectra,
obtained by averaging the Raman spectra from a labelled
k-means cluster (Fig. 2a).
This proof-of-principle study also investigated 20 indepen-
dent skin samples collected during Mohs micrographic
surgery, washed, and stored frozen (10-BCC positive and
10-BCC negative). For each sample, the frozen section histo-
pathology of the adjacent section to the investigated surface
was used as the standard of reference. For the BCC-negative
samples, an average of three false negative segments were
observed, covering less than 1% of the surface area. These
results correlated well with the observed 94% specificity. Out
of the 10-BCC positive specimens, nine were correctly diag-
nosed. The one false negative diagnosis corresponded to a
specimen that contained only a single BCC region, smaller
than 200 μm. For a typical 1 cm x 1 cm sample, the diagnosis
required 500–1500 Raman spectra, which corresponded to a
measurement time of 20–60 minutes.
These promising results led to the development of a
desktop prototype device.58 The MSH prototype was designed
to capture both auto-fluorescence images (405 nm excitation,
450–500 nm detection) and Raman spectra (785 nm excitation)
of the whole resection surface of tissue specimens loaded
within custom cassettes (Fig. 2b). The operating software was
developed to be used by clinical staff and to perform the tissue
analysis without requiring user interaction or data interpret-
ation. Results were displayed as false-colour maps, where
residual BCC was highlighted as red segments within the
detection map.
An important requirement for the analysis algorithm is
inter-instrument transferability, as the implementation of
such technology into clinical practice would require multiple
devices that use the same software. For this, the segmentation
Fig. 2 Multimodal spectral histopathology (MSH) for the detection of BCC in skin specimens: (a) k-means clustering of Raman raster scan of
different tissue types (blue arrow – BCC, green arrow – dermis, black arrow – epidermis). The centroid of each cluster shows the spectral differ-
ences between these tissue types (reproduced from ref. 46 with permission from PNAS, copyright 2013); (b) the MSH prototype device and a tissue
cassette loaded with a skin specimen; (c) evaluation of intra-user variability for the MSH prototype device: variation of tissue placement and Raman
exposure time retains the location of true BCC-positive detections; (d) evaluation of inter-user variability for the MSH prototype device: measure-
ments of tissue specimens by different users have produced comparable results (reproduced from ref. 58 with permission from © The Optical
Society, copyright 2017).
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algorithm described in Takamori et al. was adapted, to be
minimally influenced by inter-instrument variations.67 The
segmentation of auto-fluorescence images was performed by a
watershed algorithm,69 to which the texture-enhanced gradient
and the local intensity minima of morphologically flattened
auto-fluorescence images were adopted.70 Sampling points for
Raman spectroscopy were generated based on auto-fluo-
rescence intensity variance and area of the segments. The
transferability of the segmentation and sampling algorithms
was investigated by Boitor et al.58 For a dataset of 97 frozen
specimens resected via Mohs surgery from 70 patients, the
median number of BCC tumours missed due to segmentation
and sampling were the same for the two instruments. The
Raman spectral classification model, developed with spectra
from the laboratory instrument (Raman spectra were collected
as raster maps and labelled as described above46), had a per
spectrum sensitivity and specificity of 87.7% and 98.4%
respectively, via 5-fold cross validation. The same model was
then tested on spectra acquired on the prototype device,
showing a sensitivity of 81.8%% and specificity of 92.5% in
discriminating BCC from all other tissue types. Since the diag-
nosis of each segment requires multiple BCC spectral detec-
tions, the 6% decrease in classification accuracy did not influ-
ence the performance of the analysis algorithm.
The optimised analysis algorithm was then used to analyse
a set of 10 independent tissue specimens from 9 patients. In
all cases, tumours were correctly detected, as observed by com-
parison with frozen section histopathology. A small number of
false positive detections (∼6 per specimen) were observed in
both BCC-positive and BCC-negative specimens. However,
repeat measurements showed that true BCC detections were
co-localised, while the false–positive BCC segments appeared
at random locations (Fig. 2c). Repeat measurements by users
of varying spectroscopy and clinical experiences were also per-
formed for a small number of independent specimens.
Overall, comparable results were obtained from measurements
performed by a spectroscopist, a Mohs surgeon (∼1 hour of
training) and a medical trainee (∼8 hours of training) (Fig. 2d).
The instrument has been now integrated into the clinical
workflow and has demonstrated the ability to measure fresh
tissue specimens from the main anatomical sites relevant to
Mohs surgery and detect the three main types of BCC
(nodular, infiltrative and superficial).77
Selective-sampling Raman spectroscopy can also be
implemented with multi-foci Raman microscopy. In multi-foci
Raman microscopy, multiple laser beams are used to simul-
taneously measure Raman spectra from different locations of
the sample. Sinjab et al. performed multi-foci Raman spec-
troscopy by splitting a high-powered laser beam (∼3 W at
785 nm) into multiple sampling points with the use of a
liquid-crystal spatial light modulator (LC-SLM), creating a
power-shared excitation pattern for Raman spectroscopy.71 The
locations of these sampling points were controlled in real-time
with the use of the LC-SLM, allowing simultaneous acquisition
of spectra from multiple locations within a segment. A digital
micromirror device (DMD) was programmed to match the
laser excitation pattern and function as a slit, directing
Raman-scattered beams towards a spectrometer and ensuring
that high quality Raman spectra could be obtained from all
beams (Fig. 3a). The LC-SLM is used to generate specific laser
spot patterns for multi-foci Raman spectroscopy,72–75 while the
DMD in the detection path allows for dynamic selection of the
detection pattern depending on the segmented image.76 This
instrument was used to perform measurements on frozen skin
specimens, to determine whether multi-foci Raman spec-
troscopy could reduce measurements time. For this study,
15 skin specimens were investigated: 10 specimens were
raster scanned to build a spectral classification model and
five were measured using the selective sampling Raman
spectroscopy approach based on six laser foci. Acquisition and
segmentation of auto-fluorescence images were performed as
previously described,46,67 while generation of sampling points
was constrained to multiples of six within segments, as six
spectra were acquired for each 2 second exposure (Fig. 3b). All
spectra acquired within a single segment were averaged into a
single spectrum, which was classified by a Raman spectral
classification model. Each segment was therefore labelled
according to the result of this classification, on a per segment
basis.
Fig. 3 Multi-foci Raman spectroscopy to reduce multimodal spectral
histopathology (MSH) measurement speeds: (a) the LC-SLM (1) gener-
ates multiple laser foci on the sample surface (2) and the DMD (3) gener-
ated conjugated reflective pinholes, with collected light being dispersed
onto a CCD inside the spectrometer (4); (b) example of a multi-foci MSH
measurement performed on a frozen BCC-positive skin specimen
(Reproduced from ref. 71 with permission from © The Optical Society,
copyright 2016).
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The multi-foci MSH measurement presented in Fig. 3b was
captured in ∼11 minutes, with a total of 794 Raman spectra
recorded with a 2 second exposure time. The BCC tumours
seen in the adjacent frozen histology section were correctly
detected in the Raman map (red segments), showing that
multi-foci MSH could indeed reduce MSH measurements to
timeframes that are ideal for clinical translation.
Assessment of surgical margins in breast cancer surgery
Breast cancer is one of the most common cancers among
women, with more than 50,000 new cases reported in the UK
in 2019.78 Randomized trials have reported that the survival
rate of patients treated by breast conservative surgery (BCS)
paired with adjuvant therapies is similar to patients who had
radical or modified radical mastectomy.79 However, BCS has
the advantage of preventing the complete loss of breast,
improving the psychological impact on the patient.79 In case
of BCS, the rate of re-operation caused by positive margins,
detected by post-operative histology is 10–30%.80
Considering the large surface areas of the excised BCS
specimens (as large as several centimetres in diameter) and
the high spatial resolution required to detect tumours as small
as few hundred μm, faster alternatives to raster scanning
Raman spectroscopy are required.
Kong et al. were among the first to apply selective sampling
Raman spectroscopy to breast tissue samples.81 Firstly, by
using frozen tissue sections (5 mm x 5 mm, 10 μm thin), the
authors developed a classification model based on Raman
spectra that provided diagnosis of mammary ductal carcinoma
with 95.6% sensitivity and 96.2% specificity. The selective-
sampling Raman spectroscopy was achieved by integrating
auto-fluorescence (AF) imaging (365 nm excitation, 511 nm
long-pass filter for detection) and Raman spectroscopy. This
approach reduced the number of Raman spectra to a ∼20
spectra per mm2.
Shipp et al. followed this approach and combined confocal
auto-fluorescence microscopy (excitation at 405 nm, detection
450–520 nm) and Raman spectroscopy (785 nm laser) to allow
assessment of larger fresh breast tissue specimens as arriving
from surgery.24 The segmentation algorithm for the auto-fluo-
rescence image was optimised to account for patient-to-patient
variations and provided reliable, user-independent diagnosis
across a broad range of tumour types and sizes.
This technique was tested on a total of 121 tissue speci-
mens from 107 different patients.24 A classification model
based on linear discriminant analysis (LDA) was developed
using H&E staining as the standard of reference. The model
included spectra from a broad range of tumours and normal
tissues: invasive carcinoma (IC), DCIS, lobular carcinoma
in situ (LCIS), malignant phyllodes, benign proliferative lesions
(e.g. fibroadenoma, sclerosing adenosis, epithelial hyperpla-
sia), inflammation, parenchyma, normal mammary stroma,
and adipose tissue. For classification purposes, these tissue
types were grouped into three classes based on spectral simi-
larities: tumour (including invasive carcinoma, DCIS, LCIS,
and malignant phyllodes (MP)), adipose tissue, and benign/
normal non-adipose tissue. For measurements on large exci-
sion specimens, the number of Raman spectra was limited to
1000 to limit the acquisition time to 25 minutes (of which the
AF imagining step was below 10 minutes). Fig. 4 shows typical
examples of MSH measurements reporting two correctly
identified specimen with positive margins (IC and small DCIS)
and one example shows a specimen with true negative
margins.
Overall, selective-sampling Raman spectroscopy detected
breast carcinoma on the tissue resection surface with 95% sen-
sitivity and 82% specificity in less than 25 minutes (total 121
samples, up to 4 cm × 6.5 cm in size). For the 51 whole speci-
mens measured immediately after excision, selective-sampling
Raman spectroscopy detected tumours in all scanned surfaces
that had positive margins subsequently confirmed by histo-
pathology, including those with DCIS.
Fig. 4 (a) Left: Mean of Raman spectra corresponding to normal breast
tissue structures and cancer: fat (F), fat plus stroma (F+S), stroma (S),
parenchyma (P), inflamed (IN), benign (BG), other tumour types (OT),
invasive carcinoma (IC). Shadings represent the standard deviations.
Right: simplified labelling of the tissue structures grouped as tumour,
benign/healthy and fat. The spectral features used for classification are
colour coded: blue for lipid-associated bands, green for protein-associ-
ated bands, and magenta for nucleic acid-associated bands. (b)
Examples of MSH measurements of BCS specimens. The images include
wide-field pictures of the specimens, the MSH measurements and the
relevant H&E. The first two samples have positive margins, as confirmed
by the histopathology analysis. The last example was correctly identified
has having negative margins (Reproduced from ref. 24 with permission
from Breast Cancer Research, copyright 2018).
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Recently, Lizio et al.82 proposed the use of auto-fluo-
rescence spectral imaging in a total internal reflection (TIR)
imaging configuration in order to increase the efficiency of
auto-fluorescence imaging and reduce the number of Raman
spectra required for the diagnosis of large breast tissue speci-
mens. The main aim was to improve the identification of
adipose tissue by using TIR auto-fluorescence imaging, to
reserve a larger number of Raman spectroscopy measurements
to only non-adipose tissue areas. This is because, adipose
tissue accounts for most of the tumour-clear area of excised
breast tissue, therefore, fast identification of adipose tissue by
auto-fluorescence could drastically reduce the number of
Raman spectra required for investigation. The TIR configur-
ation was proposed to enable faster wide-field imaging of the
surface of the tissue specimen, while maintaining the required
spatial resolution in the lateral plane.
The authors developed a prototype instrument based on
four LEDs (365 nm wavelength, power 360 mW) aligned such
that the excitation light was waveguided in the 1 mm thick
quartz slide on which the tissue was placed. The internally
reflected light generated an evanescent field that excited auto-
fluorescence in the tissues. The emitted auto-fluorescence
light was collected by a charge-coupled device (CCD) camera
using two filters (442–488 nm and 480–562 nm), allowing for
ratiometric imaging by dividing the image collected using the
442–488 nm filter by the image collected using the
480–562 nm (Fig. 5). The ratiometric analysis proved to be
more reliable than intensity-based imaging because it was less
sensitive to inter-patient variation and contact between tissue
and quartz slide.
The TIR-Raman prototype was first tested on small tissue
samples cut out from mastectomies and the images were com-
pared with the H&E staining (typical examples showed in
Fig. 5). Adipose tissue was consistently characterised by low
ratio values in the ratiometric AF images compared to stroma
and tumour. An algorithm was used to screen out the adipose
tissue using a set threshold value of the ratio-images (0.8) and
Raman spectroscopy measurements were distributed in the
remaining regions of stroma or tumour. While still requiring
further development, as the analysis is currently done in
45 minutes with the semi-automated set up, the authors esti-
mated that analysis of whole breast resection specimens could
be completed in approximately 15 minutes once the system
will be fully automated.
Fig. 5 (a) Fluorescence emission spectra of breast tissue obtained using a 365 nm excitation wavelength. The figure reports: wide-field image of
breast tissue sample with overlaid blue dots to indicate the locations from which spectra were collected. The normalised fluorescence emission
spectra corresponding to each location measured. The H&E stained section of the sample presented with the colour coded dots corresponding to
the location from where the spectra were collected (red = tumour, blue stroma, green = adipose tissue). (b) Experiment combining TIR and Raman
spectroscopy. The figure reports: ratiometric AF image, threshold image (T < 0.8), H&E staining and the average of Raman spectra acquired from
different location of the tissue indicated by the rectangles (Reproduced from ref. 82 with permission from © The Optical Society, copyright 2020).
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While the initial studies in selective-sampling Raman spec-
troscopy employed a second optical modality for determining
the spatial properties of the sample, Liao et al. investigated the
combination of high wavenumber (HW) Raman imaging (spec-
tral range 2500–3500 cm−1) and fingerprint Raman spec-
troscopy (spectral range 600–1800 cm−1). HW-Raman imaging
was used to identify adipose tissue by targeting the C–H
stretching bands of lipids at 2700–2950 cm−1, after which the
areas identified as non-adipose were further investigated by
fingerprint Raman spectroscopy in order to provide an accu-
rate classification.54
The authors investigated several laser wavelengths to mini-
mise the interference of auto-fluorescence while attempting to
maximise the use of the spectral range where the CCD sensi-
tivity was highest. Fig. 6 shows a comparison of Raman spectra
of normal breast tissue and tumour obtained using lasers at
different wavelengths: 532 nm, 660 nm and 785 nm. The
532 nm laser generated the larger fluorescence background
that caused significant distortions of the Raman bands both
in the fingerprint and HW regions. This was particularly
apparent on the CH bands between 2850–3010 cm−1 in the
HW region which was just detectable above the fluorescence
background. The fluorescence interference was found to be
stronger for non-adipose tissue for which only the water band
∼ 3400 cm−1 was clearly detectable. Similarly, in the finger-
print region, only the bands at 1157 cm−1 and 1525 cm−1,
arising from carotenoids, were registered in the adipose tissue
above the fluorescence background. The 660 nm laser exci-
tation presented significant reduction of the fluorescence
background, with Raman bands detectable in both high-wave-
number and fingerprint regions. The HW spectra of adipose
tissue showed intense bands in the region between
2700–3000 cm−1 which are assigned to CH2 and CH3 stretching
vibrations. Non-adipose tissue reported intense Raman bands
in the 3000–3550 cm−1 region assigned to water stretching
vibrations. Lastly, the authors tested the 785 nm laser for which
the background noise was further reduced, however, the Raman
bands were not strong enough in the HW region (corresponding
to 1000–1100 nm) because of the low quantum efficiency of the
CCD. Based on these preliminary results, selective-sampling
Raman spectroscopy was performed using a 671 nm laser
acquiring HW Raman imaging followed by fingerprint Raman
point measurements at tissue locations that showed hight inten-
sity in the HW Raman images. Fig. 6, presents typical examples
of HW Raman images of breast tissue, showing that high inten-
sity regions in the HW-Raman images correspond to adipose
tissue, indicated by the green circle in the H&E staining.
The authors demonstrated that HW-Raman imaging is
effective as well as fast in screening adipose tissue, with
typical imaging times of 2 minutes for 2 cm2 tissue samples.
The authors also estimated that to analyse the whole surface of
a WLE (5 cm2) will require ∼25 min, which will make this
multimodal approach compatible with intraoperative analysis
during BCS. This study demonstrates proof-of-principle, that
faster methods for HW Raman imaging could be developed
(using high transmission interference filters and single-
element detectors rather than spectrometers with CCD) to
enable diagnosis of larger breast tissue specimens within prac-
tical times (10–20 minutes).
Conclusions and future perspectives
While the ability of Raman spectroscopy to discriminate
between normal tissue and cancerous tissue is well established,
the assessment of surgical margins for whole tissue specimens
has been limited by the long acquisition times required for
imaging large specimens. While surface enhanced Raman spec-
troscopy and coherent Raman microscopy can provide an
increase in signal intensity, selective-sampling Raman spec-
troscopy is a promising approach as it uses simple optical set-
ups to measure high-resolution Raman spectra to detect
endogenous molecular differences between tumour and normal
tissue. By optimising the sampling density of the Raman
spectra, using either adaptive sampling or multimodal imaging,
the acquisition of diagnosis maps of large tissue samples can
be completed within practical acquisition times (20–30 minutes)
while retaining the required spatial resolution.
As all steps in selective-sampling Raman spectroscopy can
be fully automated (user-independent) and can produce objec-
tive and repeatable results, the technique requires no user
interpretation and can be performed by clinical staff with
minimal training, while also being consistent across patients
and centres. Selective-sampling Raman spectroscopy results
were shown to be concordant with frozen section histopathol-
ogy for both skin and breast specimens across multiple
Fig. 6 (a) Fingerprint and high–wavenumber Raman spectra of breast
tissue samples using three different excitation wavelengths: 532 nm,
660 nm and 785 nm (red line represents adipose tissue, black line rep-
resents non adipose tissue). (b) HW–Raman images of breast tissues
(intensity scale: 0–255) and the relevant H&E section. The green circles
correspond to adipose tissue ((Reproduced from ref. 54 with permission
from Journal of Raman Spectroscopy, copyright 2020).
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devices. Depending on the tissue specimen size, typical
imaging time was 30–60 minutes (for breast and skin cancers).
Further developments such as multi-foci Raman spec-
troscopy, TIR-Raman and HW-Raman imaging have the poten-
tial to further reduce the measurement time by providing a
more tissue-specific selection of sampling points, thus
enabling more efficient use of the Raman spectra (e.g. identifi-
cation of adipose tissue in breast resections).
Nevertheless, the research so far has focused on technologi-
cal developments, including development of prototype devices
suitable for use in the clinic. The clinical integration of such
prototypes is currently underway for Mohs micrographic
surgery of BCC. Follow up studies with sufficiently large
sample sizes are required for establishing the performance of
these devices in the clinic.
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